Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF
Eric A. Murphy(University of California San Diego), David A. Cheresh(University of California San Diego), Peter K. Vogt(Scripps Research Institute), David J. Shields(Pfizer (United States)), Jeff Lindquist(University of California San Diego), Elena Dneprovskaia, Robert M. Hoffman(University of California San Diego), Lisette M. Acevedo(VistaGen Therapeutics (United States)), Igor F. Tsigelny(San Diego Supercomputer Center), Bharat K. Majeti(Pfizer (United States)), Michele McElroy(University of California San Diego), Lee D. Arnold(ArmaGen (United States)), Konstantin Stoletov(University of California San Diego), Sudarshan Anand(Cancer Institute (WIA)), Richard Klemke(Moores Cancer Center), Breda Walsh(University of California San Diego), Wolfgang Wrasidlo(University of California San Diego), Adrian Saldanha(University of California San Diego), Joshua I. Greenberg(University of California San Diego), Michael Bouvet(University of California San Diego Medical Center)
Cited by 59
Related Papers
Regulation of Cell Motility by Mitogen-activated Protein Kinase
|The Journal of Cell Biology|1997|1.2k
Spatiotemporal dynamics of RhoA activity in migrating cells
|Nature|2006|833
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
|Journal of Clinical Investigation|1995|832
CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration
|The Journal of Cell Biology|1998|669
Current Topics in Microbiology and Immunology
|Current topics in microbiology and immunology|1982|644